---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-23-000013"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:10:03.340390+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Pacira BioSciences announces director Yvonne Greenstreet to retire from board

## Summary
- Yvonne Greenstreet, independent director for 9 years, retiring effective March 31, 2023.
- Greenstreet is CEO of Alnylam Pharmaceuticals; retirement not due to any disagreement.
- Pacira will initiate search for an independent board member to replace her.

## SEC filing metadata
- accession: 0001396814-23-000013
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000013/0001396814-23-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000013/pcrx-20230318.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-23-000013
- JSON: https://secwatch.observer/filing/0001396814-23-000013.json
- Plain text: https://secwatch.observer/filing/0001396814-23-000013.txt

## Key facts
- Executive change
  Yvonne Greenstreet departed as Director at Pacira BioSciences, Inc..
  - Action: retire
  - Role: Director
  source text: On March 18, 2023, Yvonne Greenstreet notified the Board of Directors (the “Board”) of Pacira BioSciences, Inc. (the “Company”) of her intent to of her intent to retire from the Board, effective March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000013/0001396814-23-000013-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.